Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Scientists in Singapore have reported the results of an evolutionary analysis of neuraminidase, a key protein produced by the 2009 H1N1 influenza A virus strain (swine flu). In the May 20th issue of Biology Direct, Dr. Sebastian Maurer-Stroh and colleagues also demonstrated the use of a computational 3-D structural model of neuraminidase to better understand the protein.

During this week's podcast, Dr. Maurer-Stroh describes how he and his team were able to map the regions of neuraminidase that have mutated and to determine whether drugs and vaccines that target specific areas of the protein were effective. Dr. Maurer-Stroh goes on to discuss other technologies developed by scientists at Biopolis in Singapore to help them tackle H1N1. He also explains his plans for moving this research to the next phase of the study, which Bioinformatics Institute director Frank Eisenhaber has called a "significant milestone" in the use of computational biology.
Sebastian Maurer-Stroh studied theoretical biochemistry in the group of Peter Schuster at the University of Vienna and wrote his master and PhD thesis while working in Frank Eisenhaber's Group at the Institute of Molecular Pathology (IMP) in Vienna. After accepting the honor of a Marie Curie Postdoc fellowship at the VIB-SWITCH lab in Brussels, he joined the A*STAR Bioinformatics Institute (BII) in Singapore where he is currently leading a team of eight researchers to discover new biomolecular insights through protein sequence-based function predictions.

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »